Author： Wilschanski Michael Kerem Eitan
Publisher： Informa Healthcare
ISSN： 1354-3784
Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.9, 2011-09, pp. : 1285-1292
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Novel Personalised Drugs for Cystic Fibrosis
Clinical Immunology, Endocrine & Metabolic Drugs, Vol. 3, Iss. 2, 2017-08 ,pp. :
Access to resources
Recommend
New Therapies in Cystic Fibrosis
Current Pharmaceutical Design, Vol. 18, Iss. 5, 2012-02 ,pp. :
New Antimicrobial Strategies in Cystic Fibrosis
By >
Pediatric Drugs, Vol. 12, Iss. 6, 2010-12 ,pp. :
New and Emerging Therapies for Pulmonary Complications of Cystic Fibrosis
Drugs, Vol. 61, Iss. 10, 2001-01 ,pp. :
New and emerging therapies in cystic fibrosis reviewed
Inpharma, Vol. 1, Iss. 1304, 2001-01 ,pp. :